Wynt Harter Biotech Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 16-12-2024
- Paid Up Capital ₹ 0.10 M
as on 16-12-2024
- Company Age 8 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -84.24%
(FY 2020)
- Profit -80.65%
(FY 2020)
- Ebitda -80.65%
(FY 2020)
- Net Worth 1.53%
(FY 2020)
- Total Assets -53.32%
(FY 2020)
About Wynt Harter Biotech
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Raghupathy Palanisamy, Bhaskar Napa, Gopal Sampathkumar, and One other member serve as directors at the Company.
- CIN/LLPIN
U45100TN2016PTC112863
- Company No.
112863
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Oct 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Kanchipuram, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Wynt Harter Biotech?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raghupathy Palanisamy  | Whole-Time Director | 01-Mar-2021 | Current |
| Bhaskar Napa | Whole-Time Director | 01-Mar-2021 | Current |
| Gopal Sampathkumar | Whole-Time Director | 01-Mar-2021 | Current |
| Prathap Suraparaju | Whole-Time Director | 01-Mar-2021 | Current |
Financial Performance of Wynt Harter Biotech.
Wynt Harter Biotech Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 84.24% decrease. The company also saw a substantial fall in profitability, with a 80.65% decrease in profit. The company's net worth moved up by a moderate rise of 1.53%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Wynt Harter Biotech?
In 2020, Wynt Harter Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Jayam Bullion Traders LlpActive 3 years 6 monthsRaghupathy Palanisamy and Prathap Suraparaju are mutual person
- Jrps Ventures LlpActive 1 year 2 months
Raghupathy Palanisamy, Gopal Sampathkumar and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Wynt Harter Biotech?
Unlock and access historical data on people associated with Wynt Harter Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Wynt Harter Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Wynt Harter Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
